Jessie Villanueva, PhD
A novel combination therapy aimed at 2 processes implicated in NRAS-
mutant melanoma has displayed promising activity in preclinical investigations, signaling an avenue of exploration for a new therapeutic approach for patients who currently have few options.
Figure A. RAS Signaling and Downstream Targets2
There are no therapies targeting NRAS mutations, and this constitutes an urgent, unmet need for patients with melanoma, said Villanueva. “NRAS
-mutant tumors are extremely aggressive,” she said. “They rapidly metastasize to the lymph nodes, glands, and other organs.”
Figure B. BET Inhibitors at Work4
As with other anticancer strategies, researchers found that the inhibitors were not effective as monotherapy but showed impressive preclinical activity when paired and used against NRAS
-mutant melanoma with high BRD4 expression. “Targeting a single pathway or a single oncogene doesn’t really lead us to effective responses,” noted Villanueva.
... to read the full story